A Recombinant 10-kDa Protein of *Taenia solium* Metacestodes Specific to Active Neurocysticercosis

Joon-Yong Chung,1,a Young Yil Bahk,1 Sun Huh,2 Shin-Yong Kang,3 Yoon Kong,1 and Seung-Yull Cho1

Neurocysticercosis (NCC) is an important cause of neurological disease worldwide. A 10-kDa antigen of *Taenia solium* metacestodes (TsMs) has been shown to be specific for immunodiagnosis of NCC. Screening of a TsM complementary DNA (cDNA) library isolated a cDNA encoding this protein. The cloned cDNA contained a 258-bp complete open-reading frame that encodes an 86-amino acid polypeptide with a calculated molecular weight of 9582 Da. It showed 73% homology with a 10-kDa antigen of *T. crassiceps*. The recombinant protein was expressed bacterially as a fusion protein at a high level. In immunoblot with recombinant protein, 97% (184/190) of sera from patients with active NCC showed strong reactivity, whereas 14% (4/29) of those from patients with chronic calcified NCC reacted weakly. In 180 sera from other patients with parasitic infections and from normal controls, it showed 98% specificity. A single recombinant TsM antigen has a high potential for serological differentiation of active NCC.

Neurocysticercosis (NCC), which is caused by infection of the central nervous system with *Taenia solium* metacestodes (TsMs), is a major cause of neurological diseases in Asia, Africa, and Latin America [1–3]. Surveys in areas where it is endemic show that it is of public health concern, since it causes considerable mortality, chronic morbidity, and economic losses [3, 4]. Substantial evidence has shown that up to 50% of late-onset epilepsy is due to NCC [3–6]. In the United States, >1000 cases of NCC are encountered each year, mostly in immigrants [3, 7].

Diagnosis of NCC can be achieved with a high degree of accuracy by brain computed tomography/magnetic resonance imaging (CT/MRI) [8–10]. These methods are, however, expensive and inaccessible in most areas where NCC is endemic. Moreover, because the number, size, and location of NCC lesions vary and the stage of infection is often unknown, imaging diagnosis of NCC is ambiguous in many patients. The development of immunological tests that detect specific antibodies either in sera or in cerebrospinal fluid (CSF) would provide a simple and reliable adjuvant for the diagnosis of NCC. Unfortunately, most of the tests that employ crude TsM antigens lack both sensitivity and specificity; cross-reactions occur frequently with other parasitic infections, especially with cystic echinococcosis (CE) and alveolar echinococcosis (AE), which are caused by larval *Echinococcus granulosus* and *E. multilocularis*, respectively [11, 12]. Over the past 2 decades, many efforts have been directed toward characterizing specific antigens of TsMs, either from whole worm or from cyst fluid (CF) [11–16]. The low–molecular-weight antigenic components of TsMs (8–50 kDa) have attracted particular attention due to their high specificity. Immunoblot studies with TsMs found that crude soluble extracts (2 polypeptides at 8 and 26 kDa) were recognized strongly by antibodies in the serum and CSF of patients with NCC and sera from TsM-infected pigs [11, 17]. Tsang et al. [13] purified a group of glycoprotein antigens of 13–50 kDa from TsMs and undertook an immunoblot, which has been reported to be as high as 98% sensitive and 100% specific for NCC. This assay has widely been used for immunodiagnosis of individual patients and for seroepidemiological surveys [4, 18, 19].

Our research interest has been focused on the identification and isolation of specific antigens from CF of TsMs. We have previously shown that a 10-kDa antigen of TsM CF allowed high reliability in detecting the specific anti-TsM antibodies in patients with NCC [12, 15, 16]. Biochemical studies with monoclonal antibody (mAb) revealed the 10-kDa antigen is a subunit of a thermostable 150-kDa protein complex [12, 20]. In an experiment to isolate the 10-kDa protein from TsM CF either by mAb-ligand immunoaffinity chromatography [12, 20]...
Table 1. Summary of clinical and neuroimaging profiles of the patients.

| Category                          | Active NCC (n = 190) | Inactive NCC (n = 29) |
|-----------------------------------|----------------------|-----------------------|
| Age in years (mean ± SD)          | 49 ± 15              | 54 ± 15               |
| Sex (% male)                      | 65                   | 79                    |
| Symptoms                          |                      |                       |
| Headache                          | 122 (64)             | 15 (52)               |
| Seizure                           | 91 (48)              | 20 (70)               |
| Symptoms due to hydrocephalus*    | 41 (22)              | 0                     |
| Symptoms due to IICP‡              | 31 (16)              | 0                     |
| Other neurological deficits‡      | 41 (22)              | 9 (11)                |
| CT/ MRI findings                  |                      |                       |
| MLDs                              | 78 (41)              | 0                     |
| Hydrocephalus                     | 41 (22)              | 0                     |
| MLDs with calcifications          | 29 (15)              | 0                     |
| Cystic mass(es)                   | 20 (10)              | 0                     |
| MLDs with hydrocephalus           | 14 (7)               | 0                     |
| Cystic mass with calcifications   | 3 (2)                | 0                     |
| Hydrocephalus with calcifications | 2 (1)                | 0                     |
| Cystic mass with hydrocephalus    | 2 (1)                | 0                     |
| Spinal cord cysticercosis (MLDs)  | 1 (1)                | 0                     |
| Multiple calcifications           | 0                    | 29 (100)              |

NOTE. Table values are no. (%) unless otherwise indicated. NCC, neurocysticercosis; CT/ MRI, computed tomography/magnetic resonance imaging; IICP, increased intracranial pressure; MLDs, multiple low-density regions.

© Including nausea, vomiting, gait disturbance, difficulty voiding, memory loss, and dizziness.

‡ Including nausea, vomiting, stiff neck, and blurred vision; these patients’ CT/ MRI scans exhibited no evidence of hydrocephalus.

* Including dysphasia, hemo- or monoparesis, dysarthria, paresthesia, stupor, coma, and spinal cord symptoms.

Materials and Methods

**Serum samples.** A total of 219 individual serum samples from patients with NCC were selected from our serum bank. Patients were diagnosed on the basis of their clinical manifestations, brain CT/ MRI findings, and positive antibody reactions in their serum or CSF. The sera were analyzed using ELISA. Patients were categorized into 2 groups: 190 with active NCC and 29 with chronic inactive NCC. The patients who had lesions with multiple low-density regions (MLDs) or hydrocephalus compatible with NCC were classified as active cases [8, 10, 21, 22]. Patients who exhibited only multiple calcifications in their CT/MRI scan were classified as chronic inactive cases [8, 10, 22] (table 1 and figure 1). In addition, to determine possible cross-reactivity, 130 serum samples were examined from patients with AE (n = 11), CE (n = 9), sparganosis (n = 30), paragonimiasis (n = 30), clonorchiasis (n = 30), fascioliasis (n = 10), and schistosomiasis japonicum (n = 10). Normal controls (n = 50) who denied any possible exposure to helminth infection were also investigated. All serum samples were stored at −70°C until use.

**CF antigen of metacestodes from T. solium and other taenid cestodes.** TsMs were obtained from naturally infected pigs in Korea and China. After the cysts were washed, CF was collected from each with a sterile syringe [15]. CF from metacestodes of T. saginata, T. taeniformis, and T. crassiceps were collected from experimentally infected calves, rats, and mice, respectively. CF from metacestodes of E. granulosus and E. multilocularis were collected from a human patient with CE and an experimentally infected rat, respectively. The crude CF samples were centrifuged at 20,000 g for 1 h; the supernatants were used as CF antigens and stored at −70°C until use. All procedures were done at 4°C.

**Isolation of RNA and construction of cDNA library.** Fresh intact TsMs were ground in liquid nitrogen. Total RNA was isolated by CsCl gradient ultracentrifugation. Poly(A)⁺ RNA was prepared by oligo(dT)-affinity chromatography (Qiagen, Valencia, CA). cDNA was synthesized from 1 µg poly(A)⁺ RNA with the Cap-finder cDNA Library Synthesis Kit (Clontech, Palo Alto, CA). The resulting cDNA fragments were ligated into EcoRI linker DNA, then digested with EcoRI, and finally ligated with EcoRI-cleaved λgt 11 phage (all included in the Clontech Cap-finder cDNA Library kit). The recombinant DNA was packaged in Gigapack III gold packaging extract (Strategene, La Jolla, CA).

**Reverse transcription polymerase chain reaction and cloning of a cDNA encoding 10-kDa protein.** Two oligonucleotide primers were synthesized, designed on the basis of a published cDNA sequence encoding the 10-kDa immunodiagnostic antigen of T. crassiceps (TcA5.5) [23]. The sense primer was 5'-GGGAAAACAAAG-ATGAGGG-3' and the antisense primer was 5'-CTATTCAT-0. One microgram of total RNA was reverse-transcribed into cDNA by using an oligo(dT)₁₄ primer and Moloney murine leukemia virus reverse transcriptase (Gibco-BRL, Grand Island, NY). The resulting cDNA was subjected to polymerase chain reaction (PCR) amplification in a 50 µL reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl₂, 0.2 mM dNTPs, 25 pM each primer, and 2.5 units of AmpliTaq DNA polymerase (Perkin Elmer, Foster City, CA). Amplification was done in a DNA thermal cycler (9600; Perkin Elmer) for 35 cycles with denaturation at 94°C for 30 s, primer annealing at 56°C for 30 s, and extension at 72°C for 30 s with a final extension at 72°C for 5 min. The PCR product was analyzed by 1.5% agarose gel electrophoresis. A fragment of 270 bp was isolated and sequenced (described in later section). The PCR product was finally subcloned into T7 Blue T-vector (Novagen, Madison, WI).

The phage cDNA library was screened by plaque hybridization. The labeling of the probe and detection of hybridization signal were performed by using the ECL Direct Nucleic Acid Labelling and Detection System (Amersham, Buckinghamshire, UK). Both prehybridization and hybridization were done at 42°C. After sec-
ondary wash with high stringency, the membrane was autographed after a 1-min exposure. Positive plaques were isolated and the lambda DNA was purified by use of a Qiagen plasmid midikit (Qiagen). The insert was cloned into pGEM-T easy vector (Promega). An insert isolated from 1 clone harboring the expected coding sequence was excised by BamHI and SalI double digestion and ligated into the BamHI/SalI-cleaved pGEX 4T-2 expression vector (Pharmacia) and then introduced into E. coli BL21 cells carrying the DE3 bacteriophage. The fidelity of the expression construction was confirmed by DNA sequencing. Upon induction with isopropyl-β-D-thiogalactoside, the recombinant protein was expressed as a fusion with glutathione S-transferase (GST). Induced cells were harvested by centrifugation and lysed by sonication. The supernatants were adsorbed to the glutathione-Sepharose 4B resin (Pharmacia) after clearing, and the fusion protein was eluted with reduced glutathione. The GST carrier domain in fusion protein was further removed by thrombin cleavage.

Preparation of anti-recombinant TsM antibodies. Polyclonal antisera against the recombinant TsM protein were obtained from BALB/c mice immunized with purified recombinant protein. A monospecific antibody to the recombinant protein was affinity-purified from sera pooled from 10 patients with NCC by means of the SulfoLink Kit (Pierce, Rockford, IL). In brief, 10 mg of the recombinant protein was dialyzed against sodium acetate buffer (100 mM, pH 6.0), after which 6 mg of 2-mercaptoethanol was added. The mixture was then packed into a column preequilibrated with Tris buffer (50 mM, pH 8.5). A total of 5 mL of serum was eluted by glycine buffer (100 mM, pH 2.5). The monospecific antibody was dialyzed against PBS (100 mM, pH 7.2) overnight and stored at −70°C until use.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot. CF antigen preparations and recombinant protein were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA). Blots were incubated overnight, either with the patient sera or with a monospecific antibody diluted at 1:200. The murine antisera were used in appropriate dilution. Peroxidase conjugated anti-human IgG (heavy- and light-chain specific; Cappel, West Chester, PA) or anti-mouse IgG (whole molecule; Cappel) was diluted at 1:1000. The blots were developed with 0.03% (w/v) 4-chloro-L-naphthol (4CN; Sigma, St. Louis).

Results

Summary of patient characteristics. Table 1 and figure 1 show the clinical, serological, and radiological profiles of 219
patients with NCC enrolled in this study. The 190 patients in the active NCC group (123 male and 67 female patients) had a mean age of 49 ± 15 years (9–77 years). The common manifestations were headache, seizure, and symptoms due to hydrocephalus or increased intracranial pressure (IICP). In addition, some patients presented other neurological deficits such as dysphasia, hemi- or monoparesis, dysarthria, paresthesia, stupor or coma, and spinal cord syndrome. The majority of this group showed neuroimaging findings of vesicular or colloidal vesicular stage according to Escobar classification [22] and hydrocephalus with or without signs of meningeal irritation [8]. They included MLDs, hydrocephalus, cystic mass(es), MLDs mixed with calcifications or with hydrocephalus, cystic mass(es) combined with calcifications or with hydrocephalus, and hydrocephalus mixed with calcifications. Spinal cysticercosis together with MLDs was also observed in CT/MRI scans. Specific anti-TsM antibody levels, determined by ELISA employing crude CF antigen, were 0.66 ± 0.29 in sera of 190 patients and 0.89 ± 0.38 in CSF of 152 patients examined (the other 38 were not tested). Cut-off absorbance for positive reaction was 0.18 in both serum and CSF [21].

The chronic calcified inactive group consisted with 29 patients whose antibody titer in serum was marginal or negative (0.11 ± 0.07) and positive in CSF (0.25 ± 0.07) (figure 1). Chronic NCC tended to show positive reactions only in CSF but not in the sera [14, 21, 24]. These cases included 23 male and 6 female patients. Their mean age was 54 ± 15 years (19–83 years). Clinical symptoms included seizure, headache, and other neurological deficits such as hemiparesis, dysphasia, motor weakness, dizziness, and dementia. All the patients exhibited multiple calcifications in their neuroimages.

Cloning and molecular properties of a cDNA encoding 10-kDa protein. The antigenic similarity of the 10-kDa protein among genus *Taenia* shown in studies published elsewhere [23, 25] suggested a sequence homology of these related genes. We succeeded in amplifying a TsM cDNA fragment using a degenerate primer derived from a published cDNA sequence of a 10-kDa immunodiagnostic antigen of *T. crassiceps* (TcA5.5) [23]. We

---

### Figure 2

**A.** Nucleotide and deduced amino acid sequence of a cDNA encoding a *Taenia solium* metacestode (TsM) 10-kDa antigen. Note the complete nucleotide sequence of 372 bp with an open-reading frame of 258 bp. The start and stop codons (ATG and TAG, respectively) are boldface; asterisk (*) indicates stop codon. A putative polyadenylation signal (AATAAA) is underlined. A highly hydrophobic polypeptide sequence is italicized and underlined. Potential N-glycosylation sites are indicated in black boxes.

**B.** Alignment of deduced amino acid sequence of TsM 10-kDa protein with 2 known taeniid antigens. Gaps indicated by dots are introduced into the sequence to optimize the alignment. Other markings are same as in A. The percentage homologies are shown at the end of each polypeptide. The 10-kDa immunodiagnostic antigen of *T. crassiceps* [23] and 8-kDa antigen of *Echinococcus granulosus* (subunit of antigen B) [36] are shown for comparison.

---

Downloaded from https://academic.oup.com/jid/article-abstract/180/4/1307/845663 by guest on 30 July 2018
In vitro expression and characterization of a recombinant protein. In a preliminary observation, we tried to express the full-length coding domain (258 bp), although only a small amount of recombinant protein was expressed as insoluble aggregates. We prepared a truncated fragment of 198 bp without the N-terminal hydrophobic sequence. In this case, the recombinant protein was expressed at a high level in a soluble form and could be efficiently purified by glutathione-affinity chromatography. As shown in figure 3A, GST-fusion protein migrated to 33 kDa in SDS-PAGE analysis. After the GST carrier was removed by thrombin cleavage, the purified protein moved as a single band at $\sim$7 kDa, which is in good agreement with what we calculated from the cDNA sequence. In immunoblot analysis (figure 3B), both the 33-kDa GST-TsM fusion protein and the 7-kDa TsM protein reacted strongly with serum pooled from 10 patients with NCC as well as with the antibodies generated (immunoblots probed by monospecific antibody and mouse antiserum not shown). On the other hand, no reactivity was observed at the 26-kDa GST band, which suggests that the presence of GST carrier domain in the recombinant protein did not affect the antigenicity (figure 3B, lane b). We have designated recombinant 33-kDa GST-fusion TsM protein as cysticercosis diagnostic antigen (CyDA) and directly used it in further serological evaluation.

Figure 4 shows the immunoblot outcome probed with a mon-
specific antibody purified from patients with NCC by using CyDA. The proteins at ~10 kDa in CFs from all *Taenia* species, including *T. solium*, *T. saginata*, *T. crassiceps*, and *T. taeniacformis*, were recognized by the monospecific antibody despite a minor difference in electrophoretic mobility, possibly due to their different degree of, or lack of, glycosylation [20, 23, 25]. The CF antigens from *E. granulosus* and *E. multilocularis* did not show a positive reaction at 10 kDa. This comparative immunoblot analysis confirms the common presence of the 10-kDa protein in genus *Taenia*. Notably, the 15- and 7-kDa bands in TsM CF were also reactive with the monospecific antibody, which further supports the presumption that the 10-kDa protein is a subunit of the 150-kDa complex of TsM CF [12, 20].

**Evaluation of the diagnostic value of CyDA.** To assess the diagnostic value of CyDA, we further tested its immunoreactivity by a large-scale immunoblot assay using individual sera from patients with various helminthic infections. A typical result of the immunoblot analysis is shown in figure 5. A strong recognition of CyDA was observed in 97% (184/190 cases) of sera from patients with active NCC who were examined, whereas only 14% (4/29 cases) of those from patients with chronic NCC showed a weak reaction. Weak cross-reactivity was observed in only 1 of each serum sample from patients with AE, sparganosis, and clonorchiasis cases (figure 5, panels C, E, and G, respectively). None of the sera from patients with other parasitic infections or from normal controls showed any antibody reactivity. Overall sensitivity and specificity of CyDA were determined to be 97% and 98%, respectively (table 2).

The serum antibody reactivity in patients with NCC, determined by immunoblot assay using CyDA, appeared to be relatively consistent with those determined by ELISA that employed the crude CF (figure 6).

**Discussion**

In this study, we have sequenced a cDNA encoding TsM 10-kDa protein and expressed it as a GST-fusion protein in *E. coli*. Immunoblot analysis of the recombinant protein showed that it has a high potential for serological differentiation of active NCC not only from other parasitic infections but also from chronic inactive NCC.

Effective immunodiagnosis of parasitic diseases depends largely on the availability of well-defined specific antigens. In the case of human and swine cysticercosis as well as bovine cysticercosis (caused by *T. saginata* metacestodes), the difficulties experienced in collecting the metacestodes led researchers to attempt to employ cross-reactive antigenic components from more readily available taenid cestodes as substitute antigens [23, 25–30]. Several studies have shown that a 10-kDa protein in CF of *T. hydatigena* metacestodes is useful for serological diagnosis of human NCC [25] and for bovine cysticercosis [27, 30]. The 10-kDa protein was subsequently found to be shared among metacestodes of *T. saginata* and *T. crassiceps* [23, 25, 31]. This is also true for TsMs [12, 15, 16] and is confirmed by our comparative immunoblot analysis, in which we employed CF antigens of various taenid metacestodes, described in this study.

![Figure 5](https://academic.oup.com/jid/article-abstract/180/4/1307/845663)

**Table 2.** Sensitivity and specificity of immunoblot analysis in sera from patients with neurocysticercosis and other parasitic infections, and normal controls, by use of the recombinant 10-kDa protein of *Taenia solium* metacestodes.

| Parasitic infection or control group | No. of cases | No. (%) of positive reactions |
|-------------------------------------|--------------|------------------------------|
| Neurocysticercosis                  | 213          | 188 (88)                     |
| Active neurocysticercosis           | 190          | 184 (97)                     |
| Chronic neurocysticercosis          | 29           | 4 (14)                       |
| Alveolar echinococcosis             | 11           | 1 (9)                        |
| Cystic echinococcosis               | 9            | 0 (0)                        |
| Sparganosis                         | 30           | 1 (3)                        |
| Paragonimiasis                      | 30           | 0 (0)                        |
| Clonorchiasis                       | 30           | 1 (3)                        |
| Fascioliasis                        | 10           | 0 (0)                        |
| Schistosomiasis                     | 10           | 0 (0)                        |
| Normal controls                     | 50           | 0 (0)                        |

A strong positive reaction is shown only in cases with active NCC. Lanes a–o each represent a different patient.
Figure 6. Correlation between reactivity of serum in immunoblot assay with cysticercosis diagnostic antigen and serum in ELISA with the crude cyst fluid antigen. Horizontal dashed line indicates cut-off absorbance (abs.) at 0.18. The typical immunoblot responses of weak, moderate, and strong reactions are shown below the figure. ●, active neurocysticercosis (NCC); ○, inactive NCC.

The finding that the 10-kDa antigen of TsMs is highly useful for immunodiagnosis of NCC [12, 15, 16] has stimulated our interest in cloning the gene that encodes the protein. The common epitope shared between metacestodes of different Taenia species suggests that it might be possible to exploit the inherent antigenic similarity of a 10-kDa protein to clone the corresponding genes. We designed oligonucleotides on the basis of a published cDNA sequence of 10-kDa antigen of T. crassiceps and used them as PCR primers to amplify the homologous cDNA fragment. We obtained a 270-bp cDNA sequence and, by screening a TsM cDNA library with this fragment, isolated a 372-bp cDNA encoding a 10-kDa TsM protein.

Sequence analysis revealed that the 372-bp cDNA sequence was closely related to, but clearly different from, the cDNA sequence encoding the 10-kDa antigen of T. crassiceps metacestodes. The N-terminus of the deduced protein was shown to contain a highly hydrophobic region, which might be the transmembrane domain that is possibly finished by signal peptidase [32] or might be a site for hydrophobic interaction with other molecules that have a biological reactivity other than specific antigenicity [25]. Cloning and characterization of the gene encoding a TsM 10-kDa protein may be an important contribution to the further definition of the genetic relationship among 10-kDa proteins shared in different Taenia species.

The major symptoms of active NCC were headache, seizure, and the symptom complex due to hydrocephalus and IICP, whereas those of chronic cases were seizure and headache. Presumably, persistent inflammatory reactions mounted by active immune surveillance of the host cause several symptoms associated with active NCC [33–35]. In chronic NCC, on the other hand, the long-standing inflammation caused by mumified worms served as an abnormal epileptogenic focus, stimulating seizures by intensive gliosis, or produced migraine-type headaches [8, 10, 24]. Differential diagnosis of active NCC from patients with chronic inactive cases is important to establish the appropriate treatment for affected patients, because symptoms due to chronic calcified NCC are not caused by the parasites per se, but by the sequelae of granuloma and residual calcifications, which did not respond to the anticysticercal drug [8, 10]. However, there are few serological methods currently available to assess worm viability in patients. The CyDA described in the present study showed high sensitivity and specificity in differentiating active from chronic NCC. Expression of a recombinant protein that provides an abundant source of high-quality antigen for immunoblot analysis has a definite merit [28].

In the present study, we have shown that CyDA appears to have a potential for the discrimination of active NCC from chronic inactive NCC. However, there were many patients in whom brain CT/MRI revealed both MLDs and calcifications (n = 29), hydrocephalus with calcifications (n = 2), or cystic mass with calcifications (n = 3). These patients were difficult to identify as active or not active. In this study, we classified them as active cases according to criteria given elsewhere [8, 22]. Indeed, they all showed the positive reactions found in active cases, judged by immunoblot outcome with CyDA. There were 6 patients whose brain CT/MRI exhibited pathognomonic findings of the vesicular stage but who showed no reactions to CyDA (figure 6). Sera and CSF from these patients also showed relatively weak positive reactions to crude CF antigen by ELISA (0.32 ± 0.18; figure 1). This discrepancy between neuroimaging findings in patients with active-stage NCC and immunoblot analysis of sera, which shows low levels of specific antibody with no reactivity against CyDA, may argue against the high reliability of CyDA as a specific antigen for NCC. However, many studies have shown that some of NCC patients may undergo immune tolerance or decreased immunity [10, 36], which suggests that nonresponsiveness is not due to antigenic properties but to the immunological status of the infected in-

Figure 6. Correlation between reactivity of serum in immunoblot assay with cysticercosis diagnostic antigen and serum in ELISA with the crude cyst fluid antigen. Horizontal dashed line indicates cut-off absorbance (abs.) at 0.18. The typical immunoblot responses of weak, moderate, and strong reactions are shown below the figure. ●, active neurocysticercosis (NCC); ○, inactive NCC.
individuals. Specific antibodies in these patients may react with other antigenic molecules of TsMs. Further elucidation of the natural course of the parasite infection according to infection stage and clinical course, and of immunological responses against the parasite, is required.

It will be of particular interest to investigate whether CyDA is useful for serological screening of TsM-infected pigs. Because T. solium splits its life cycle between humans and pigs, the control of porcine cysticercosis is crucial for control of human NCC [2, 4, 36]. We are currently analyzing the serum antibody responses against CyDA in TsM-infected pigs. Pilot experiments with several serum samples have shown encouraging results.

In conclusion, CyDA, as characterized in this study, offers promises of effective serological differentiation not only between NCC and other parasitic infections, but also between active and chronic inactive NCC. Its potential for serodiagnosis of TsM-infected pigs is proposed. We expect that our results shown here and ongoing studies may contribute ultimately to the successful control and prevention of NCC.

Acknowledgments

We are grateful to Dr. L. Ma, National Institutes of Health, Bethesda, for his critical review of the manuscript. We are also indebted to Dr. C. Jiang, Department of Anti-helminthiasis, Henan Provincial Anti-epidemic Station, Zhengzou, Henan, and Drs. Z. Feng and K. Xue, Shanghai Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shanghai, for their help in collecting metacestodes from pigs infected with T. solium.

References

1. Craig PS, Rogan MT, Allan JC. Detection, screening and community epidemiology of taenid cestode zoonoses: cystic echinococcosis, alveolar echinococcosis and neurocysticercosis. Adv Parasitol 1996;38:169-250.

2. Simanjuntak GM, Margono SS, Okamoto M, Ito A. Taeniasis/cysticercosis in Indonesia as an emerging disease. Parasitol Today 1997;13:321-3.

3. White AC Jr. Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 1997;24:101-13.

4. Tsang VC, Wilson M. Taenia solium cysticercosis: an under-recognized but serious public health problem. Parasitol Today 1995;11:124-6.

5. Medina MT, Rosas E, Rubio-Donnadieu F, Sotelo J. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med 1990;150:325-7.

6. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru. Lancet 1993;341:197-200.

7. Schantz PM, Moore AC, Munoz JL, et al. Neurocysticercosis in an orthodox Jewish community in New York City. N Engl J Med 1992;327:692-5.

8. Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms. A study of 753 cases. Arch Intern Med 1985;145:442-5.

9. Chang KH, Kim WS, Cho SY, Han MC, Kim CW. Comparative evaluation of brain CT and ELISA in the diagnosis of neurocysticercosis. Am J Neuroradiol 1988;9:125-30.

10. Del Brutto OH, Wadia NH, Dumas M, Cruz M, Tsang VC, Schantz PM. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci 1996;142:1-6.

11. Gottstein B, Tsang VC, Schantz PM. Demonstration of species-specific and cross reactive components of T. solium metacestode antigens. Am J Trop Med Hyg 1986;35:308-13.

12. Kong Y, Cho SY, Kim SI, Kang SY. Immunoelectrophoretic analysis of major component proteins in cystic fluid of Taenia solium metacestodes. Kisa-engchungak Chapchi 1992;30:269-18.

13. Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989;159:50-9.

14. Simac C, Michel P, Andriantsimahavandy A, Esterre P, Michault A. Use of enzyme-linked immunosorbent assay and enzyme-linked immunoelectrotransfer blot for the diagnosis and monitoring of neurocysticercosis. Parasitol Res 1995;81:132-6.

15. Yang HJ, Chung JY, Yun DH, et al. Immunoblot analysis of a 10 kDa antigen in cyst fluid of Taenia solium metacestodes. Parasite Immunol 1998;20:483-8.

16. Ito A, Planctare A, Ma L, et al. Novel antigens for neurocysticercosis: simple method for preparation and evaluation for serodiagnosis. Am J Trop Med Hyg 1998;59:291-4.

17. Rodriguez-Canal R, Allan JC, Domínguez JL, et al. Application of an immunoblot assay to determine risk factors associated with porcine cysticercosis in rural areas of Yucatan, Mexico. Vet Parasitol 1998;79:165-80.

18. Wilson M, Bryan RT, Fried JA, et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991;164:1007-9.

19. Schantz PM, Sarti E, Planctare A, et al. Community-based epidemiological investigations of cysticercosis due to Taenia solium: comparison of serological screening tests and clinical findings in two populations in Mexico. Clin Infect Dis 1994;18:879-85.

20. Cho SY, Kim SI, Kang SY, Kong Y. Biochemical properties of a purified protein in cystic fluid of Taenia solium metacestodes. Korean J Parasitol 1988;26:87-94.

21. Cho SY, Kim SI, Kang SY, et al. Evaluation of enzyme-linked immunosorbent assay in serological diagnosis of human neurocysticercosis using paired samples of serum and cerebrospinal fluid. Korean J Parasitol 1998;26:25-41.

22. Escobar A. The pathology of neurocysticercosis. In: Palacio E, Rodriguez-Cabajar J, Taveras JM, eds. Cysticercosis of the central nervous system. Springfield: Thomas, 1983:27-54.

23. Zarlanga DS, Rhoads ML, Al-Yaman FM. A Taenia crassiceps cDNA sequence encoding a putative immunodiagnostic antigen for bovine cysticercosis. Mol Biochem Parasitol 1994;67:215-23.

24. Del Brutto OH, Sotelo J, Roman GC, eds. Neurocysticercosis: a clinical handbook. Lisse: Swets & Zeitlinger Publishers, 1998.

25. Hayunga EG, Sunner MP, Rhoads ML, Murrell KD, Isenstein RS. Development of a serological assay for cysticercosis, using an antigen isolated from Taenia spp cyst fluid. Am J Vet Res 1991;52:462-70.

26. Fernandez V, Ferreira HB, Fernandez C, Zaha A, Nieto A. Molecular characterization of a novel 8-kDa subunit of Echinococcus granulosus antigen B. Mol Biochem Parasitol 1996;77:247-50.

27. Kamanga-Sollo EI, Rhoads ML, Murrell KD. Evaluation of an antigenic fraction of Taenia hydatigena metacestode cyst fluid for immunodiagnosis of bovine cysticercosis. Am J Vet Res 1987;48:1206-10.

28. Vaz AJ, Nunes CM, Piazza RM, et al. Immunoblot with cerebrospinal fluid from patients with neurocysticercosis using antigen from cysticerci of Taenia solium and Taenia crassiceps. Am J Trop Med Hyg 1997;57:354-7.

29. Garcia HH, Tsang VC, Gilman RH. A high degree of cross reactivity between the antigens of Taenia solium and Taenia crassiceps, potentially useful for the diagnosis of human neurocysticercosis [letter]. Am J Trop Med Hyg 1998;59:693-4.

30. Rhoads ML, Murrell KD, Dilling GW, Wong MM, Baker NF. A potential diagnostic reagent for bovine cysticercosis. J Parasitol 1985;71:779-87.
31. Gevorkian G, Manoutcharian K, Larralde C, et al. Immunodominant synthetic peptides of *Taenia crassiceps* in murine and human cysticercosis. *Immunol Lett* 1996;49:185–9.

32. Von Henge G. A new method for predicting signal sequence cleavage site. *Nucleic Acids Res* 1986;14:4683–90.

33. Ostrosky-Zeichner L, Garcia-Mendoza E, Rios C, Sotelo J. Humoral and cellular immune response within subarachnoid space of patients with neurocysticercosis. *Arch Med Res* 1996;27:513–7.

34. Pittella JE. Neurocysticercosis. *Brain Pathol* 1997;7:681–93.

35. Evans CA, Garcia HH, Hartnell A, et al. Elevated concentrations of eotaxin and interleukin-5 in human neurocysticercosis. *Infect Immun* 1998;66:4522–5.

36. White AC, Robinson P, Kuhn R. *Taenia solium* cysticercosis: Host-parasite interactions and immune response. In: Freedman DO, ed. Immunopathogenetic aspect of diseases induced by helminth parasites. Chemical Immunology. Basel: Karger, 1997;66:209–30.